Baseline gut microbial characteristics may serve as potential biomarkers of heterogeneous treatment response in young adults with irritable bowel syndrome, distinguishing distinct multidimensional response phenotypes.
In a secondary analysis of a randomized controlled trial (NCT03332537) with 62 participants, two distinct symptom-trajectory phenotypes were identified: a Constrained Response Phenotype (n=35) and an Adaptive Multidomain Response Phenotype (n=27). Baseline gut microbiota taxa and predicted functional pathways differed between phenotypes and predicted treatment response to pain self-management interventions, with phenotype-specific predictors such as Alistipes and Sutterella for Phenotype A and Phascolarctobacterium, Collinsella, and Parabacteroides for Phenotype B.
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
Baseline gut microbial characteristics may serve as potential biomarkers of heterogeneous treatment response in young adults with irritable bowel syndrome, distinguishing distinct multidimensional response phenotypes. The current body of evidence comprises 1 study, including 1 randomized controlled trial. EvidenceHub rates the overall confidence at 42/100 (low).
The Claim
Baseline gut microbial characteristics may serve as potential biomarkers of heterogeneous treatment response in young adults with irritable bowel syndrome, distinguishing distinct multidimensional response phenotypes.
This conclusion is most relevant to: Young adults with irritable bowel syndrome (IBS) from a randomized controlled trial (n=62 with longitudinal data).
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸Gut microbiota signatures differentiate trajectory-defined response phenotypes and predict self-management outcomes in irritable bowel syndrome. (Frontiers in microbiomes, 2026) —
How It Works
The proposed biological pathway:
- ▸Baseline gut microbiota composition and functional pathways are assessed.
- ▸Distinct microbial taxa and pathways are associated with different symptom-trajectory phenotypes.
- ▸These microbial features predict longitudinal changes in pain and quality of life outcomes.
- ▸Microbiome-based categorization may enable personalized self-management strategies for IBS.
Who Might Benefit
Evidence fit by population:
- ▸Young adults with irritable bowel syndrome (IBS) from a randomized controlled trial (n=62 with longitudinal data)
Recommended Dose
N/A
Limitations & Caveats
Important context when interpreting this evidence:
- ▸Predicted functional pathway differences were not significant after correction for multiple testing.
- ▸Small sample size (n=62) and single trial context limit generalizability.
- ▸The study is a secondary analysis, not a primary outcome analysis.
- ▸Microbial predictors were identified via BART models but may not be causal.
Frequently Asked Questions
What are the two response phenotypes in IBS?▼
The two phenotypes are the Constrained Response Phenotype (Phenotype A) and the Adaptive Multidomain Response Phenotype (Phenotype B). Phenotype B showed lower baseline pain but higher anxiety, depression, and fatigue, and demonstrated broad improvements across neuropsychological domains and quality of life, while Phenotype A had more limited improvements.
Can gut microbiota predict IBS treatment response?▼
Yes, the study found that baseline gut microbial taxa and functional features were predictive of treatment response in BART models. For example, Alistipes and Sutterella were predictors for Phenotype A, while Phascolarctobacterium, Collinsella, and Parabacteroides were predictors for Phenotype B.
What interventions were tested in this study?▼
The abstract mentions pain self-management interventions, but specific details are not provided in the abstract. The trial is registered as NCT03332537.
What is the clinical significance of these findings?▼
The findings suggest that baseline gut microbiota could serve as biomarkers to categorize IBS patients and personalize self-management strategies, potentially improving treatment outcomes.
References
- 1.Chen J, Li A, Wu W, Xu W, Zhao T, Starkweather AR, Rodriguez L, Chen MH, Cong XS. “Gut microbiota signatures differentiate trajectory-defined response phenotypes and predict self-management outcomes in irritable bowel syndrome..” Frontiers in microbiomes, 2026. PMID: 42592264 DOI: 10.3389/frmbi.2026.1884540